ROBO GLOBAL HEALTHCARE TECHNOLOGY AND
INNOVATION ETF

Fund Description


For over five years, ROBO Global has researched healthcare and life sciences companies as part of its Robotics, Automation and AI investment strategies. Say hello to HTEC - an index tracking ETF with 50-100 Healthcare Technology and Innovation companies from around the world capturing this investment opportunity. The ROBO Global® Healthcare Technology and Innovation ETF (HTEC) seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the ROBO Global® Healthcare Technology and Innovation Index.

DATA AS OF: 12/10/2019

Primary Exchange NYSE Arca
Ticker HTEC
CUSIP 301505723
Net Assets $4,556,208.27
# of Equity Holdings 87
Fund Inception Date June 25, 2019
Gross Expense Ratio 0.80%
Net Expense Ratio* 0.68%
Shares Outstanding 175,001

NET ASSET VALUE

NAV $26.04
Daily Change $0.10
Daily Change (%) 0.39%

MARKET PRICE

Closing Price $26.08
Daily Change $0.09
Daily Change (%) 0.35%

*The Advisor has contractually agreed to waive fees through August 31, 2020.

Healthcare technology & innovation – the opportunity


Healthcare is undergoing a dramatic, technology-driven revolution. The convergence of robotics, machine intelligence and life sciences has enabled breakthrough advances from AI-powered diagnostic to minimally invasive robotic surgery, from molecular analysis to DNA sequencing and genetic cancer therapies, from 3D printed implants to virtual care visits.

We anticipate that this technology revolution should profoundly transform the healthcare industry, offering a potential opportunity to investors over the next decade. It is about shifting the model from caring for the sick to one of prevention, prediction and eradication of diseases. It is about enhancing physicians’ accuracy and therapies’ efficacy. Finally, it is about lowering costs. The expected result: longer, healthier lifespans.

Methodology


ROBO Global performs fundamental and industry research to establish a classification of disruptive healthcare technologies including medical instruments, diagnostics, robotics, genomics, precision medicine, lab automation, data analytics, regenerative medicine and telehealth. Companies involved in the various sectors of the classification are then evaluated for technology and market leadership, as well as revenue and investment exposure, resulting in a composite “HTEC score”. The ROBO Global HTEC Index is composed of companies with a high HTEC score that also pass ROBO Global's Environmental, Social and Governance (ESG) policy requirements. We reconstitute and rebalance the index to modified equal weights on a quarterly basis. HTEC scores are reviewed based on continuous research, engagement with company management teams and market developments.

PERFORMANCE


MONTH END AS OF: 11/30/2019

Cumulative (%) Avg Annualized (%)
1 Month 3 Month YTD Since Inception 1 Year 3 Year 5 Year Since Inception
Fund NAV 9.34% 8.79% TBD 8.48% TBD TBD TBD TBD
Market Price 9.28% 8.82% TBD 5.56% TBD TBD TBD TBD
QUARTER END AS OF: 09/30/2019

Cumulative (%) Avg Annualized (%)
1 Month 3 Month YTD Since Inception 1 Year 3 Year 5 Year Since Inception
Fund NAV -3.18% -5.44% TBD -3.46% TBD TBD TBD TBD
Market Price -3.13% -5.51% TBD -6.04% TBD TBD TBD TBD

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor`s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the original cost. Returns for periods of less than one year are not annualized. Returns are determined based on the midpoint of the bid/ask spread at 4:00pm Eastern time, when the NAV is typically calculated. Market returns does not represent the returns you would receive if you traded shares at other times.

Top 10 Holdings as of 12/10/2019

Name Ticker Shares Market Value % of Market Value % of Net Assets
ARROWHEAD PHARMA ARWR 1799 127,477.14 2.798% 2.798%
DEXCOM INC DXCM 368 79,315.04 1.741% 1.741%
ALIGN TECHNOLOGY INC ALGN 284 77,716.60 1.706% 1.706%
TELADOC HEALTH INC TDOC 989 77,250.79 1.695% 1.696%
QIAGEN N.V. QGEN 1803 75,149.04 1.649% 1.649%
ILLUMINA INC ILMN 228 74,542.32 1.636% 1.636%
STAAR SURGICAL CO STAA 1978 73,542.04 1.614% 1.614%
NATERA INC NTRA 1923 71,997.12 1.58% 1.58%
PENUMBRA INC PEN 449 71,157.52 1.562% 1.562%
REGENERON PHARMACEUTICALS REGN 193 70,960.31 1.557% 1.557%

Fund holdings and sector allocations are subject to change at any time and should not be considered recommendations to buy or sell any security.

Distributions


SIGN UP TO RECEIVE THE LATEST UPDATES ABOUT HTEC

Please check your email after submitting.




Exchange Traded Concepts, LLC serves as the investment advisor of the fund. The Fund is distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Exchange Traded Concepts, LLC or any of its affiliates. Check the background of SIDCO on FINRA’s BrokerCheck.

Carefully consider the Fund's investment objectives, risk factors, charges and expenses before investing. This and additional information can be found on the Funds' full or summary prospectus, which may be obtained at www.roboglobaletfs.com. Read the prospectus carefully before investing.

Investing involves risk, including the possible loss of principal. International investments may also involve risk from unfavorable fluctuations in currency values, differences in generally accepted accounting principles, and from economic or political instability. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Narrowly focused investments and investments in smaller companies typically exhibit higher volatility. There is no guarantee the fund will achieve its stated objective.

The liquidity of the A-shares market and trading prices of Ashares could be more severely affected than the liquidity and trading prices of other markets because the Chinese government restricts the flow of capital into and out of the A-shares market. The Fund may experience losses due to illiquidity of the Chinese securities markets or delay or disruption in execution or settlement of trades.

These risks associated with investments in Robotics and Automation Companies include, but are not limited to, small or limited markets for such securities, changes in business cycles, world economic growth, technological progress, rapid obsolescence, and government regulation. Robotics and Automation Companies, especially smaller, start-up companies, tend to be more volatile than securities of companies that do not rely heavily on technology. Rapid change to technologies that affect a company's products could have a material adverse effect on such company's operating results. Robotics and Automation Companies may rely on a combination of patents, copyrights, trademarks and trade secret laws to establish and protect their proprietary rights in their products and technologies. There can be no assurance that the steps taken by these companies to protect their proprietary rights will be adequate to prevent the misappropriation of their technology or that competitors will not independently develop technologies that are substantially equivalent or superior to such companies' technology.

Diversification may not protect against market risk.

Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Market price returns are based upon the midpoint of the bid/ask spread at the close of the exchange and does not represent the returns an investor would receive if shares were traded at other times. Brokerage commissions will reduce returns. NAVs are calculated using prices as of 4:00 PM Eastern Time.

BUY ROBO GLOBAL ETFS

×

Buy ROBO Global ETFs

Select the ROBO Global ETF that
you would like to trade.

ROBO

ROBO Global Robotics & Automation
Index ETF

HTEC

ROBO Global Healthcare Technology and Innovation ETF